Argitalpenak (42) MANUEL DELGADO ALVARADO argitalpenak

2023

  1. A novel clinical sign to assess the risk of Parkinson’s disease in patients with isolated asymmetric arm swing

    Neurological Sciences, Vol. 44, Núm. 4, pp. 1401-1404

  2. Interactions between functional networks in Parkinson's disease mild cognitive impairment

    Scientific Reports, Vol. 13, Núm. 1

  3. Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study

    Frontiers in Immunology, Vol. 14

2022

  1. Neurogenetic traits outline vulnerability to cortical disruption in Parkinson's disease

    NeuroImage: Clinical, Vol. 33

  2. Parkinsonism Associated With Striatal Enlarged Perivascular Spaces

    Neurology

  3. Teriflunomide-induced Raynaud’s phenomenon: a serious adverse event, previously unreported

    Neurological Sciences

2021

  1. Amyotrophic lateral sclerosis (ALS), cancer, autoimmunity and metabolic disorders: An unsolved tantalizing challenge

    British Journal of Pharmacology, Vol. 178, Núm. 6, pp. 1269-1278

  2. Does Extended Interval Dosing Natalizumab Preserve Effectiveness in Multiple Sclerosis? A 7 Year-Retrospective Observational Study

    Frontiers in Immunology, Vol. 12

  3. Imaging Cognitive Impairment and Impulse Control Disorders in Parkinson's Disease

    Frontiers in Neurology, Vol. 12

  4. Predictive value of prolactin in first episode psychosis at ten years follow-up

    Revista de Psiquiatria y Salud Mental, Vol. 14, Núm. 3, pp. 179-180

  5. Serial DaT-SPECT imaging in asymptomatic carriers of LRRK2 G2019S mutation: 8 years’ follow-up

    European Journal of Neurology, Vol. 28, Núm. 12, pp. 4204-4208

2020

  1. A novel SGCE variant is associated with myoclonus-dystonia with phenotypic variability

    Neurological Sciences, Vol. 41, Núm. 12, pp. 3779-3781

  2. Correction to: Motor impulsivity and delay intolerance are elicited in a dose-dependent manner with a dopaminergic agonist in parkinsonian rats (Psychopharmacology, (2020), 237, 8, (2419-2431), 10.1007/s00213-020-05544-6)

    Psychopharmacology

  3. Disrupted salience network dynamics in Parkinson's disease patients with impulse control disorders

    Parkinsonism and Related Disorders, Vol. 70, pp. 74-81

  4. Functional inhibitory control dynamics in impulse control disorders in Parkinson's disease

    Movement Disorders, Vol. 35, Núm. 2, pp. 316-325

  5. Motor impulsivity and delay intolerance are elicited in a dose-dependent manner with a dopaminergic agonist in parkinsonian rats

    Psychopharmacology, Vol. 237, Núm. 8, pp. 2419-2431

  6. Nonpharmacological, nonsurgical treatments for freezing of gait in Parkinson's disease: A systematic review

    Movement Disorders, Vol. 35, Núm. 2, pp. 204-214

2019

  1. Nigrostriatal dopamine transporter availability, and its metabolic and clinical correlates in Parkinson’s disease patients with impulse control disorders

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 46, Núm. 10, pp. 2065-2076

  2. Plasma prolactin levels are associated with the severity of illness in drug-naive first-episode psychosis female patients

    Archives of Women's Mental Health, Vol. 22, Núm. 3, pp. 367-373

  3. Pramipexole-induced impulsivity in mildparkinsonian rats: a model of impulse control disorders in Parkinson's disease

    Neurobiology of Aging, Vol. 75, pp. 126-135